

Certificate of Analysis

Human Glial Cell-Line Derived Neurotrophic Factor (rhGDNF):

Part No. Size
G278A 5 μ g

Description: Human Glial Cell-Line Derived Neurotrophic Factor (rhGDNF) is a 30kDa homodimer consisting of two disulfide-linked, 134-amino acid subunits. rhGDNF is produced from recombinant DNA expressed in *E. coli*.

Rehydration: The dried rhGDNF is soluble in water and most aqueous buffers. Reconstitute in water to a final concentration of 0.1mg/ml. This solution can be diluted into other buffered solutions or stored at -20°C for up to three months.

Storage Conditions: Store desiccated at -20°C. See the expiration date on the product information label. Store reconstituted rhGDNF in aliquots at -20°C, where it is stable for three months. Avoid multiple freeze-thaw cycles and exposure to frequent temperature changes.

Usage Note: The actual weight of dried factor is not confirmed after the material has been dried down and may vary from the weight indicated on the product label. If the exact weight of factor to be used is important, we recommend that the amount of material in the vial be assayed before use.

Part# 9PIG278

Revised 8/13



AF9PI G278 0813G278

Quality Control Assays

Identity: The identity of rhGDNF is verified by ELISA assay using Anti-Human GDNF pAb (Cat.# G2791) for detection. A multiwell plate is coated with rhGDNF diluted serially from 10 μ g/ml to 0.01 μ g/ml; rhGDNF is detected with Anti-Human GDNF pAb at a concentration of 1 μ g/ml. The half-maximal absorbance under these conditions must occur at an rhGDNF concentration \leq 1 μ g/ml.



Promega

Promega Corporation

2800 Woods Hollow Road	
Madison, WI 53711-5399	USA
Telephone	608-274-4330
Toll Free	800-356-9526
Fax	608-277-2516
Internet	www.promega.com

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

Promega manufactures products for a number of intended uses. Please refer to the product label for the intended use statements for specific products. Promega products contain chemicals which may be harmful if misused. Due care should be exercised with all Promega products to prevent direct human contact.

Each Promega product is shipped with documentation stating specifications and other technical information. Promega products are warranted to meet or exceed the stated specifications. Promega's sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. Promega makes no other warranty of any kind whatsoever, and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO PROMEGA PRODUCTS. In no event shall Promega be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Promega products to perform in accordance with the stated specifications.

© 1997-2013 Promega Corporation. All Rights Reserved.

E_{max} is a registered trademark of Promega Corporation.

All specifications are subject to change without prior notice.

Product claims are subject to change. Please contact Promega Technical Services or access the Promega online catalog for the most up-to-date information on Promega products.

Signed by:

J. Stevens

J. Stevens, Quality Assurance

Part# 9PIG278
Printed in USA. Revised 8/13

1. Description

Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) is processed from a 211-amino acid precursor protein to form a mature homodimer of two 134-amino acid subunits. GDNF possesses seven cysteine residues and forms three disulfide bonds resulting in a 'cysteine knot' quaternary structure. Discovered by Lin *et al.* in 1993 and shown to be a potent survival factor for dopaminergic neurons (1), GDNF has since been shown to be a potent survival factor for spinal motoneurons (2–4), locus ceruleus noradrenergic neurons (5) and distinct subpopulations of peripheral sensory, sympathetic and parasympathetic neurons (6,7). A surprising finding from studies in GDNF-null mice was that the animals failed to develop kidneys and form the enteric nervous system (8–10).

The receptor complex for GDNF has been elucidated. GDNF interacts with the receptor tyrosine kinase, Ret, formerly an orphan receptor (11–16). Yet GDNF can only bind Ret through a membrane-tethered accessory protein, identified as GDNFR- α (11,12). Since the members of this multicomponent receptor family are growing, new terminology has been proposed, specifically that GDNFR- α be referred to as GFR α -1, for TGF β -related neurotrophic factor receptor 1, and other such accessory factors be named accordingly (17). A review of GDNF can be found in references 18 and 19, and a review of the GDNF/neurturin receptor complex can be found in reference 20.

2. Standard Applications

Use rhGDNF to investigate neuronal physiology. Applications include:

- Examination of the survival of sensory and motor neurons (3) and dopamine neurons (21).
- Investigation of dopamine metabolism (22).
- Protection from dopamine neuron loss (21–23).

3. Related Products

E_{max}[®] ImmunoAssay Systems

Product	Size	Cat.#
BDNF E _{max} [®] ImmunoAssay Systems	5 × 96 wells	G7611
	2 × 96 wells	G7610
NGF E _{max} [®] ImmunoAssay Systems	5 × 96 wells	G7631
	2 × 96 wells	G7630
GDNF E _{max} [®] ImmunoAssay Systems	5 × 96 wells	G7621
	2 × 96 wells	G7620

Items Available Separately

Product	Size	Cat.#
Anti-Human GDNF pAb	200 μ g	G2791
Anti-Human NT-3 pAb	200 μ g	G1651
mNGF, 2.5S	100 μ g	G5141

Product	Size	Cat.#
Anti-NGF mAb	100 μ g	G1131
Anti-Human p75 pAb	200 μ g	G3231
rhBDNF	5 μ g	G1491
Anti-Human BDNF pAb	200 μ g	G1641

4. References

1. Lin, L.-F. *et al.* (1993) *Science* **260**, 1130–32.
2. Henderson, C.E. *et al.* (1994) *Science* **266**, 1062–64.
3. Oppenheim, R.W. *et al.* (1995) *Nature* **373**, 344–6.
4. Yan, Q., Matheson, C. and Lopez, O.T. (1995) *Nature* **373**, 341–4.
5. Arenas, E. *et al.* (1995) *Neuron* **15**, 1465–73.
6. Buj-Bello, A. *et al.* (1995) *Neuron* **15**, 821–8.
7. Trupp, M. *et al.* (1995) *J. Cell Biol.* **130**, 137–48.
8. Pichel, J.G. *et al.* (1996) *Nature* **382**, 73–6.
9. Sánchez, M.P. *et al.* (1996) *Nature* **382**, 70–3.
10. Moore, M.W. *et al.* (1996) *Nature* **382**, 76–9.
11. Treanor, J.J.S. *et al.* (1996) *Nature* **382**, 80–3.
12. Jing, S. *et al.* (1996) *Cell* **85**, 1113–24.
13. Trupp, M. *et al.* (1996) *Nature* **381**, 785–9.
14. Durbec, P. *et al.* (1996) *Nature* **381**, 789–93.
15. Vega, Q.C. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**, 10657–61.
16. Liu, X. *et al.* (1996) *J. Biol. Chem.* **271**, 5309–12.
17. GFR α Nomenclature Committee (1997) *Neuron* **19**, 485.
18. Lin, L.-F. (1996) *Neural Notes* **7**, 3–7.
19. Rosenthal, A. (1999) *Neuron* **22**, 201–7.
20. Rosenthal, A. (1997) *Neural Notes* **9**, 3–7.
21. Beck, K.D. *et al.* (1995) *Nature* **373**, 339–41.
22. Lin, L.-F. *et al.* (1994) *J. Neurochem.* **63**, 758–68.
23. Tomac, A. *et al.* (1995) *Nature* **373**, 335–9.